Corcept Therapeutics Incorporated
CORT
$71.38
$0.921.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.53% | 33.04% | 55.19% | 33.15% | 24.89% |
| Total Depreciation and Amortization | -3.75% | -43.44% | -65.36% | -75.17% | -51.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.27% | -0.91% | -39.85% | -11.78% | -2.43% |
| Change in Net Operating Assets | 652.47% | 451.19% | -107.91% | -145.18% | -358.31% |
| Cash from Operations | 43.74% | 55.91% | -6.40% | -8.53% | 12.43% |
| Capital Expenditure | -1,537.41% | -1,462.59% | -1,106.47% | 6.40% | 65.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.11% | -292.69% | -265.84% | -199.63% | -187.09% |
| Cash from Investing | -36.77% | -295.37% | -269.97% | -200.21% | -187.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 86.87% | 65.48% | 85.23% | 46.19% | 38.18% |
| Repurchase of Common Stock | 49.21% | 75.43% | 79.29% | 91.71% | -640.48% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.76% | 80.94% | 84.61% | 96.34% | -800.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.10% | -111.39% | -58.59% | -131.96% | -163.08% |